User profiles for Robert J. de Knegt
 | Robert De KnegtGastroenterologist & Hepatologist, Erasmus MC University Medical Center Verified email at erasmusmc.nl Cited by 5726 |
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
…, L Kuske, S Zeuzem, WP Hofmann, RJ De Knegt… - Jama, 2012 - jamanetwork.com
… Dr de Knegt reported that his institution received financial compensation for consultancy
and/or lecture activities or patents from Merck, Janssen, Roche, Gilead, and Medtronic, and …
and/or lecture activities or patents from Merck, Janssen, Roche, Gilead, and Medtronic, and …
[HTML][HTML] Objectives, design and main findings until 2020 from the Rotterdam Study
…, BCT Kieboom, CCW Klaver, RJ de Knegt… - European journal of …, 2020 - Springer
The Rotterdam Study is an ongoing prospective cohort study that started in 1990 in the city of
Rotterdam, The Netherlands. The study aims to unravel etiology, preclinical course, natural …
Rotterdam, The Netherlands. The study aims to unravel etiology, preclinical course, natural …
[PDF][PDF] Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus
…, J Reichen, WP Hofmann, RJ de Knegt… - …, 2008 - Wiley Online Library
Recent studies suggest that diabetes mellitus increases the risk of developing hepatocellular
carcinoma (HCC). The aim of this study is to quantify the risk of HCC among patients with …
carcinoma (HCC). The aim of this study is to quantify the risk of HCC among patients with …
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
…, E Croes, RJ de Knegt, V de Ledinghen… - The lancet …, 2017 - thelancet.com
Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and
mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting …
mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting …
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
Background & Aims The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated
among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who …
among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who …
[PDF][PDF] Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases
…, P Hartmann, M Thiele, L Caballeria, RJ de Knegt… - …, 2022 - Wiley Online Library
Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering
progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver …
progressive fibrosis. Currently, the main etiologies of cirrhosis are non‐alcoholic fatty liver …
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
…, Y Oo, J Petersen, F Van Bömmel, RJ De Knegt… - Gut, 2015 - gut.bmj.com
Background Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir
(ETV)-treated patients. We aimed to study risk factors and performance of risk scores …
(ETV)-treated patients. We aimed to study risk factors and performance of risk scores …
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: focusing on the non‐overlap groups
…, LA van Kleef, LJM Alferink, P Li, RJ de Knegt… - Liver …, 2022 - Wiley Online Library
Background & Aims The applicability of the novel metabolic dysfunction associated fatty liver
disease (MAFLD) definition has been studied in numerous cohorts and compared to non‐…
disease (MAFLD) definition has been studied in numerous cohorts and compared to non‐…
Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment
…, BE Hansen, HLA Janssen, RJ de Knegt… - The Journal of …, 2016 - academic.oup.com
Background. Chronic hepatitis C virus (HCV) infection is a global health problem, resulting
in liver failure, hepatocellular carcinoma, and liver-related death. Natural killer (NK) cells are …
in liver failure, hepatocellular carcinoma, and liver-related death. Natural killer (NK) cells are …
Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis
MAA Claassen, RJ de Knegt, HW Tilanus… - Journal of …, 2010 - Elsevier
BACKGROUND & AIMS: Weak hepatitis C virus (HCV) specific immunity in peripheral blood
has been shown to be partially controlled by regulatory T cells (Treg). However, little is …
has been shown to be partially controlled by regulatory T cells (Treg). However, little is …